Navigation Links
GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
Date:11/4/2010

ATLANTA, Nov. 4, 2010 /PRNewswire/ -- GeoVax Labs, Inc. (OTCQB/OTC Bulletin Board: GOVX), an Atlanta-based, biopharmaceutical firm dedicated to developing vaccines that prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced that it has been awarded a grant of $244,500 related to its HIV/AIDS vaccine development activities under the Qualifying Therapeutic Discovery Project ("QTDP") program. GeoVax received the maximum level allowable under the program based on the high number of applicants.

The QTDP program was created by the U.S. Congress as part of the Patient Protection and Affordable Care Act of 2010. It was intended to provide incentive to smaller companies who are focusing on innovative therapeutic discoveries. QTDP grants or tax credits are awarded to companies with fewer than 250 employees for projects related to the treatment or prevention of diseases through the conduct of pre-clinical or clinical studies

The grant was awarded following GeoVax's submission for consideration of its HIV/AIDS vaccine research and development project to the U.S. Secretary of Health and Human Services. Among the determining factors used by the Secretary in allocating funds were those projects that show potential to produce new therapies, address unmet medical needs, and reduce the long-term growth of healthcare costs. Also taken into consideration were the potential for projects to create and sustain high-quality, high-paying U.S. jobs and to advance U.S. competitiveness in the fields of life, biological and medical sciences.

"We are delighted to be the beneficiary of this grant at the maximum level available," said President and CEO Robert T. McNally, PhD. "This grant was allocated following favorable federal review of our project submission, which we believe reflects the potential of our HIV/AIDS vaccine program. These funds and other grant sources continue to support GeoVax's ongoing clinical programs."

About GeoVax Labs, Inc.GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus – that leads to AIDS) and other infectious agents. Our goals include developing HIV/AIDS vaccines for global markets, overseeing the manufacture and testing these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as, the vaccines' safety. Successful results from Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVax's Phase 2 human trial began in January 2009 and will ultimately involve 300 participants at sites in the United States and South America. Recently GeoVax began enrolling patients in a Phase 1 therapeutic trial for individuals already infected with HIV. For more information, please visit www.geovax.com.

Forward-Looking StatementsCertain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.  GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so.  More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.ContactAt the Investor Relations Group:Investor Relations:James Carbonara / Jason StromingerorPublic Relations:Janet Vasquez / Robin O'Malley(212) 825-3210
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GeoVax Labs Engages The Investor Relations Group
2. GeoVax Labs, Inc. Reports Fourth Quarter and Year End 2009 Financial Results
3. GeoVax Labs, Inc. Plans Public Offering
4. GeoVax Labs, Inc. Begins Enrollment at Final Site for Preventative Vaccine; Next Step Is to Submit IND Application for Therapeutic Vaccine to FDA
5. FDA Grants GeoVax Labs, Inc. Request For Pre-IND Meeting
6. GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update
7. GeoVax Labs, Inc. Announces Results of 2009 Annual Shareholders Meeting
8. Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine
9. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
10. GeoVaxs Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America
11. GeoVax Reports Progress on Its AIDS Vaccine Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... , Jan. 16, 2017 Summary ... Outlook to 2022", provides key market data on the ... in millions of US dollars, volume (in units) and ... X-Ray Absorptiometry (DEXA) and Quantitative Ultrasound (QUS). The ... for each of these market segements, and global corporate-level ...
(Date:1/16/2017)... 2017 Infusion pumps and accessories are ... medications in a controlled, precise and automated manner. ... in critical care, pain management and other applications, ... feel comfortable and pain free. These infusion systems ... to serious life threatening circumstances or even sometimes ...
(Date:1/16/2017)...  Verathon ® Inc., a leading manufacturer and marketer of ... ® Spectrum TM Single-Use video laryngoscopes. The ... Ambient Light Reduction TM technology, which actively optimizes image quality. ... ... Introducing another bright idea from GlideScope(R) ...
Breaking Medicine Technology:
(Date:1/16/2017)... (PRWEB) , ... January 17, 2017 , ... Recently, patients ... in Southwest Michigan, joined other volunteers and organizations in support of the annual Binder ... children and families dressed up in colorful costumes of all designs coming out to ...
(Date:1/16/2017)... ... January 16, 2017 , ... Etymotic Research, makers of ... EB15•LE® electronic earplugs at the NSSF SHOT Show on January 17-20, 2017 at ... Show is the shooting, hunting and outdoor trade show and conference for the ...
(Date:1/16/2017)... Houston, TX (PRWEB) , ... January 16, 2017 ... ... dental office , Antoine Dental Center, is currently offering complimentary consultations and ... can have their teeth examined for bite irregularities and learn about their orthodontic ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... of the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol for ... to understand the scope of their EHS regulatory obligations and rapidly collect, share, ...
(Date:1/16/2017)... OR (PRWEB) , ... January 16, 2017 , ... ... author, editor, attorney, science teacher, http://www.ageofautism.com/legal , Sharon Kleyne, America’s leading ... Kent Heckenlively to her nationally syndicated radio program, The Sharon Kleyne Hour Power ...
Breaking Medicine News(10 mins):